Gland Pharma Receives Zero Form 483 Observations from USFDA
Gland Pharma Ltd · Others (Uncategorized) · 01 Sept 2026, 9:19 pm
Gland Pharma Receives Zero Form 483 Observations from USFDA Gland Pharma announced the conclusion of a USFDA inspection at its VSEZ Sterile Oncology Formulations and API Facility in Visakhapatnam. The routine Good Manufacturing Practice (GMP) inspection, conducted from 24th Aug’26 to 1st Sep’26, concluded with ZERO (0) Form 483 observations. This favorable outcome is a significant positive, indicating compliance with US regulatory standards and mitigating risks of supply disruptions from this key facility. The company stated there is no financial or operational impact.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation · 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs · 16 Nov 2026
- Grant of Options to Purchase Securities · 16 Nov 2026
- Q2FY27 Earnings Call Transcript · 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company · 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 · 09 Nov 2026
- Q2FY27 Earnings Call Recording · 07 Nov 2026
- Q2Fy27 Investors presentation · 06 Nov 2026
